Abstract
Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.
| Original language | English |
|---|---|
| Pages (from-to) | 93-101 |
| Number of pages | 9 |
| Journal | European Journal of Pharmacology |
| Volume | 271 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 12 1994 |
Fingerprint
Keywords
- Autoradiography
- Chronic CGP 39551
- Hippocampus
- NMDA receptor
- Quinolinic acid neurotoxicity
- [H]Noradrenaline release
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
- Pharmacology
Cite this
Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. / Mennini, Tiziana; Miari, Anna; Presti, Maria Laura; Rizzi, Massimo; Samanin, Rosario; Vezzani, Annamaria.
In: European Journal of Pharmacology, Vol. 271, No. 1, 12.12.1994, p. 93-101.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551
AU - Mennini, Tiziana
AU - Miari, Anna
AU - Presti, Maria Laura
AU - Rizzi, Massimo
AU - Samanin, Rosario
AU - Vezzani, Annamaria
PY - 1994/12/12
Y1 - 1994/12/12
N2 - Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.
AB - Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.
KW - Autoradiography
KW - Chronic CGP 39551
KW - Hippocampus
KW - NMDA receptor
KW - Quinolinic acid neurotoxicity
KW - [H]Noradrenaline release
UR - http://www.scopus.com/inward/record.url?scp=0027944726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027944726&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(94)90269-0
DO - 10.1016/0014-2999(94)90269-0
M3 - Article
C2 - 7698217
AN - SCOPUS:0027944726
VL - 271
SP - 93
EP - 101
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1
ER -